Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects

AIM: Cannabinoid receptor type 1 (CB(1)) antagonists show central side effects, whereas beneficial effects are most likely peripherally mediated. In this study, the peripherally selective CB(1) antagonist TM38837 was studied in humans. METHODS: This was a double-blind, randomized, placebo-controlled...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Klumpers, Linda E, Fridberg, Marianne, de Kam, Marieke L, Little, Paul B, Jensen, Niels Ole, Kleinloog, Hendrik D, Elling, Christian E, van Gerven, Joop M A
Format: Artigo
Langue:Inglês
Publié: Blackwell Science Inc 2013
Sujets:
Clinical Trials
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3845308/
https://ncbi.nlm.nih.gov/pubmed/23601084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12141
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires